… In the following discussion, we will go over these potential therapeutic options for COVID-induced
lung fibrosis, including pirfenidone and nintedanib, both of which have been approved …

… for post-COVID pulmonary fibrosis are not completely … evidence of post-COVID-19 pulmonary
fibrosis, including the potential … In this context, the potential determinants of post-COVID-19 …

… The most critically ill patients in the context of SARS-CoV-2 infection, develop acute … the
pulmonary fibrotic disease observed after COVID-19 recovery (33). Pirfenidone exerts anti-fibrotic…

… died from coronavirus disease 2019 (COVID-19) worldwide. 1 Almost all COVID-19-related …
2 In the first large series of hospitalised patients (n= 138) with COVID-19 in Wuhan, China, …

… IPF who develop COVID-19 pneumonia, acute lung injury, and … the fibrotic consequences for
patients who survive COVID-19-… background, patients with progressive pulmonary fibrosis in …

… lung disease (ILD). We then review the current literature on the proposed mechanisms of
lung injury in severe COVID-19 … the development of post-COVID-19 pulmonary fibrosis (PCPF). …

… context, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus
responsible for the current coronavirus disease 2019 (COVID-19) … development of fibrotic lesions …

… , we hypothesize that lung fibrosis may be also a possible long-term consequence of
COVID-19 pneumonia. Assessing the long-term consequences of COVID-19 thus appears crucial. …

… the context of COVID-19, rehabilitation is being delivered by various virtual models,
including video linked classes and home education booklets with additional telephone support.…

… activity in mouse PCLS (266) and might be an interesting treatment strategy in the context
of COVID-19 given the acquisition of a senescence-like phenotype in SARS-CoV-2 infected …